We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Colorectal Carcinoma Tumor Budding Automatically Evaluated

By LabMedica International staff writers
Posted on 10 Sep 2018
Print article
Image: The M8 serves as a dual microscope and scanner with all features accessible via a touch screen computer, making it a truly digital microscope (Photo courtesy of PreciPoint).
Image: The M8 serves as a dual microscope and scanner with all features accessible via a touch screen computer, making it a truly digital microscope (Photo courtesy of PreciPoint).
Tumor budding, meaning a detachment of tumor cells at the invasion front of colorectal carcinoma (CRC) into single cells or clusters has been shown to correlate to an inferior clinical outcome by several independent studies.

However, the application of tumor budding by manual evaluation in routine pathology is hampered due to the use of several slightly different assessment systems, a time-consuming manual counting process and a high inter-observer variability.

Pathologists led by their colleagues at the University Medical Centre Mannheim (Mannheim, Germany) retrieved 20 whole-slide tissue specimens of formalin-fixed paraffin-embedded tumor tissue and tissue microarray (TMAs) of tumor tissue from the Medical University of Graz (Graz, Austria). These cases belong to a previously published patient cohort of 381 patients (166 males, 215 females; median age 70.1 years).

The team combined classical segmentation methods (like morphological operations) and machine learning techniques (k-means and hierarchical clustering, convolutional neural networks) to reliably detect tumor buds in colorectal carcinoma samples immunohistochemically stained for pan-cytokeratin. As a possible application, they tested it on whole-slide images as well as on tissue microarrays (TMA) from the clinically well-annotated CRC cohort. The sequential sections were digitalized as whole-slide images (WSI) using a digital microscope and M8 scanner (PreciPoint GmbH, Freising, Germany).

The scientists reported that their automatic tumor budding evaluation tool detected the absolute number of tumor buds per image with a very good correlation to the manually segmented ground truth. Furthermore the automatic evaluation of whole-slide images from 20 CRC-patients, they found that neither the detected number of tumor buds at the invasion front nor the number in hotspots was associated with the nodal status. However, the number of spatial clusters of tumor buds (budding hotspots) significantly correlated to the nodal status. TMAs were not feasible for tumor budding evaluation, as the spatial relationship of tumor buds (especially hotspots) was not preserved.

The authors concluded that on the basis of a combination of image processing and machine learning, they found that not the absolute number of tumor formations classified as “tumor buds” within the infiltrative region but rather their spatial arrangement in significant hotspots and especially the number of such hotspots is clinically meaningful. Consequently, the advice for the surgical pathologist is to focus more on the spatial distribution (as kind of pattern diagnosis), rather than on the absolute number, of tumor buds. The study was published on August 28, 2018, in the journal Diagnostic Pathology.

Related Links:
University Medical Centre Mannheim
Medical University of Graz
PreciPoint
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.